证券日报网讯甘源食品9月30日在互动平台回答投资者提问时表示，公司将持续关注国际市场机遇，积 极拓展国内外销售渠道，充分发挥休闲食品研发创新优势，提升产品竞争力，努力提高各渠道销售规 模。同时，公司将通过优化治理水平，持续开展现金分红、加强信息披露和投资者关系管理等合规方 式，提升公司投资价值，维护股东的利益。 （文章来源：证券日报） ...

Summary of Sanara MedTech (SMTI) 2025 Conference Call Company Overview - **Company**: Sanara MedTech (SMTI) - **Industry**: Medical Technology, specifically in wound care and surgical products - **Key Personnel**: Newly appointed CEO Seth Young and CFO Elizabeth Taylor Core Points and Arguments - **Leadership Transition**: Seth Young has been with the company for eight years, moving through various roles before becoming CEO, effective September 15, 2025 [1][2][3] - **Company Growth**: Initially a single product company, Sanara has expanded its offerings to include a range of products from soft tissue to bone fusion and repair [6][8] - **Strong Q2 Performance**: The company reported a 25.8% growth in Q2, driven by balanced performance in both soft tissue and bone repair products, with significant contributions from anchor products BioSurge and Celerate [11][12] - **Operational Efficiency**: The company has generated cash from operations, leveraging existing sales force without significant expansion, indicating a focus on operational efficiency [14][17] - **Market Expansion**: While core markets remain in orthopedics and spine, the company is exploring opportunities in foot and ankle, plastics, and vascular spaces [20][21] - **Distributor Network**: Sanara has over 400 contracted distributors, which are crucial for expanding market reach and driving sales [22][23][35] - **Clinical Evidence**: The company emphasizes the importance of clinical data to support product efficacy, which is gathered through case studies and research [24][25] - **Strategic Review of THP**: Sanara is exploring strategic alternatives for its THP business, considering options such as partnerships or potential sale [27][28] - **Product Pipeline**: The company is excited about the upcoming launch of Ostic in 2027, a bio-adhesive product for trauma cases, which has received FDA breakthrough designation [29][30][31] Additional Important Insights - **Management Team Development**: The senior management team has been strengthened, positioning the company for future growth [17][32] - **Focus on Core Competencies**: The company aims to maintain focus and discipline in its core surgical business while exploring new growth opportunities [33][36] - **Sales Force Strategy**: The current strategy does not foresee a significant increase in internal sales staff but emphasizes the growth of the distributor network [22][35] - **Future Growth Drivers**: The company plans to leverage existing contracts and expand its reach within the 4,000 contracted facilities, currently selling into just over 1,000 [36] This summary encapsulates the key points discussed during the Sanara MedTech conference call, highlighting the company's growth trajectory, strategic initiatives, and future outlook.